
News|Poll|March 27, 2015
Have You Heard This (Week's) News?
Author(s)Susan Kweskin
Advertisement
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.
Eylea (aflibercept) injection is also indicated for treatment of which of the following?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial
2
Longitudinal Blood Biomarkers Show Promise for Monitoring Alzheimer's Disease Progression in Subjective Cognitive Decline
3
Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis
4
Quality Improvement Program Greatly Expands Sleep Apnea Testing After Stroke in VA Hospitals
5
























































































































































































































































































